You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》輝瑞次季盈利勝預期 新冠產品銷量跌 降全年營收預測
阿思達克 08-01 20:47
輝瑞(PFE.US)公布,由於新冠病毒相關產品銷量暴跌,今年第二季銷售額按年下跌54%至127.3億美元(下同),低於市場預期的132.7億元。季度利潤為23.3億元,遠遜於去年同期的99.1億元;經調整每股盈利為0.67元,高於市場預期的0.57元。 公司於第二季的新冠疫苗銷售額為14.9億元,較去年同期下降83%;新冠抗病毒藥物「Paxlovid」銷售額則為1.43億元,按年跌98%。 輝瑞將今年銷售額預測由670億元至710億元,降至介乎670億元至700億元,並重申全年經調整每股盈利預測為3.25元至3.45元。公司同時預計今年與新冠病毒相關的銷售額將下降,重申今年新冠疫苗銷售額預計為135億元,「Paxlovid」收入為80億元的預測。 業績公布後公司周二(1日)美股盤前靠穩,微升0.3%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account